ATE354572T1 - Substituierte 1-piperidin-4-yl-4-azetidin-3-yl- piperazinderivate und deren verwendung als neurokininantagonisten - Google Patents

Substituierte 1-piperidin-4-yl-4-azetidin-3-yl- piperazinderivate und deren verwendung als neurokininantagonisten

Info

Publication number
ATE354572T1
ATE354572T1 AT03799583T AT03799583T ATE354572T1 AT E354572 T1 ATE354572 T1 AT E354572T1 AT 03799583 T AT03799583 T AT 03799583T AT 03799583 T AT03799583 T AT 03799583T AT E354572 T1 ATE354572 T1 AT E354572T1
Authority
AT
Austria
Prior art keywords
disorders
sub
diseases
neurokinin
emesis
Prior art date
Application number
AT03799583T
Other languages
English (en)
Inventor
Frans Eduard Janssen Janssens
Francois M Sommen
Boeck Benoit C De
Joseph E Leenaerts
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE354572T1 publication Critical patent/ATE354572T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
AT03799583T 2002-12-23 2003-12-17 Substituierte 1-piperidin-4-yl-4-azetidin-3-yl- piperazinderivate und deren verwendung als neurokininantagonisten ATE354572T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP0214837 2002-12-23

Publications (1)

Publication Number Publication Date
ATE354572T1 true ATE354572T1 (de) 2007-03-15

Family

ID=32668703

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03799583T ATE354572T1 (de) 2002-12-23 2003-12-17 Substituierte 1-piperidin-4-yl-4-azetidin-3-yl- piperazinderivate und deren verwendung als neurokininantagonisten

Country Status (9)

Country Link
US (1) US7435736B2 (de)
EP (1) EP1581517B1 (de)
JP (1) JP4660199B2 (de)
AT (1) ATE354572T1 (de)
AU (1) AU2003299249B2 (de)
CA (1) CA2509406C (de)
DE (1) DE60312042T2 (de)
ES (1) ES2282731T3 (de)
WO (1) WO2004056800A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060019587A (ko) 2003-06-11 2006-03-03 머크 앤드 캄파니 인코포레이티드 치환된 3-알킬 및 3-알케닐 아제티딘 유도체
JP4948395B2 (ja) 2004-04-13 2012-06-06 インサイト・コーポレイション ケモカインレセプターアンタゴニストとしてのピペラジニルピペリジン誘導体
WO2006051489A1 (en) * 2004-11-10 2006-05-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases
GB0514017D0 (en) * 2005-07-07 2005-08-17 Ionix Pharmaceuticals Ltd Chemical compounds
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
WO2010124121A1 (en) * 2009-04-22 2010-10-28 Jansen Pharmaceutica Nv Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitor
EP2421848A1 (de) 2009-04-22 2012-02-29 Janssen Pharmaceutica N.V. Azetidinyldiamide als monoacylglycerinlipaseinhibitoren
US8435977B2 (en) 2009-04-22 2013-05-07 Janssen Pharmaceutica, Nv Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors
AU2011296068B2 (en) 2010-09-03 2015-07-09 Janssen Pharmaceutica Nv Di-azetidinyl diamide as monoacylglycerol lipase inhibitors
EP2621918A1 (de) * 2010-09-27 2013-08-07 Janssen Pharmaceutica, N.V. Oxopiperazin-azetidinamide und oxodiazepin-azetidinamide als monoacylglycerol-lipasehemmer
EP2630139A1 (de) 2010-10-22 2013-08-28 Janssen Pharmaceutica, N.V. Amino-pyrrolidin-azetidindiamide als monoacylglycerollipasehemmer
US8513423B2 (en) 2010-10-22 2013-08-20 Janssen Pharmaceutica, Nv Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors
KR102115060B1 (ko) * 2012-12-27 2020-05-25 알즈프로텍트 N-(3-(4-(3-(디이소부틸아미노)프로필)피페라진-1-일)프로필)-1H-벤조[d]이미다졸-2-아민의 황산염들, 이들의 제조 방법 및 그것의 용도
WO2015200594A2 (en) 2014-06-25 2015-12-30 Emory University Methods of managing conditioned fear with neurokinin receptor antagonists
JP6640840B2 (ja) * 2014-09-22 2020-02-05 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 線維症を処置するための方法及び医薬組成物
MA46228A (fr) * 2016-09-14 2019-07-24 Janssen Pharmaceutica Nv Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll
CN109689663B (zh) 2016-09-14 2023-04-14 詹森药业有限公司 Menin-mll相互作用的螺二环抑制剂
US10745409B2 (en) 2016-12-15 2020-08-18 Janssen Pharmaceutica Nv Azepane inhibitors of menin-MLL interaction
US11458129B2 (en) 2017-11-02 2022-10-04 California Institute Of Technology Neurokinin antagonists and uses thereof
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
CA3217423A1 (en) 2021-06-16 2022-12-22 Jeffrey M. Schkeryantz Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY110227A (en) 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
NZ321575A (en) 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
GB9600235D0 (en) * 1996-01-05 1996-03-06 Pfizer Ltd Therapeutic agents
GB9714129D0 (en) * 1997-07-04 1997-09-10 Pfizer Ltd Azetidines
AU7788500A (en) 1999-10-25 2001-05-08 Janssen Pharmaceutica N.V. Use of substance p antagonists for influencing the circadian timing system
GB0025354D0 (en) * 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
US6642226B2 (en) * 2001-02-06 2003-11-04 Hoffman-La Roche Inc. Substituted phenyl-piperidine methanone compounds
FR2820426B1 (fr) * 2001-02-07 2007-05-11 Condat Sa Gel d'isolation thermique a reticulation controlee pour les lignes de transport d'hydrocarbures petroliers

Also Published As

Publication number Publication date
JP2006512349A (ja) 2006-04-13
DE60312042D1 (de) 2007-04-05
EP1581517A1 (de) 2005-10-05
US7435736B2 (en) 2008-10-14
DE60312042T2 (de) 2007-10-31
EP1581517B1 (de) 2007-02-21
AU2003299249B2 (en) 2010-05-27
AU2003299249A1 (en) 2004-07-14
ES2282731T3 (es) 2007-10-16
WO2004056800A1 (en) 2004-07-08
CA2509406C (en) 2012-07-03
CA2509406A1 (en) 2004-07-08
US20060074069A1 (en) 2006-04-06
JP4660199B2 (ja) 2011-03-30

Similar Documents

Publication Publication Date Title
ATE354572T1 (de) Substituierte 1-piperidin-4-yl-4-azetidin-3-yl- piperazinderivate und deren verwendung als neurokininantagonisten
MY141736A (en) Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists
TW200500359A (en) Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
DE60212110D1 (de) Triazaspiro (5.5) undecanderivate und arzneimittel, die diese derivate als wirkstoff enthalten
ATE283854T1 (de) Triazaspiro(5.5)undecan-derivate und drogen, die dasselbe als aktiven inhaltsstoff enthalten
TW200604198A (en) Substituted diaza-spiro-[4.5]-decane derivatives and their use as neurokinin antagonists
MXPA05010055A (es) Derivados de 2-fenoxi- y 2-fenil-sulfomamida con actividad antagonista del ccr3, para el tratamiento del asma y otros desordenes inflamatorios o inmunologicos.
EA200601880A1 (ru) Замещенные производные 4-алкил- и 4-алканоилпиперидина и их применение в качестве антагонистов нейрокининов
TW200602339A (en) Substituted diaza-spiro-[5.5]-undecane derivatives and their use as neurokinin antagonists
EA200701879A1 (ru) Замещённые производные оксадиазаспиро [5.5] ундеканона и их применение в качестве антагонистов нейрокинина
HRP20050554A2 (en) Substituted 1-piperidin-3-yl-4-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists
WO2008077810A3 (en) Spiro-piperidine derivatives
MX2009005541A (es) Indoles que actuan como antagonistas del receptor v1a.
MX2009005504A (es) Derivados de espiro piperidina como antagonistas del receptor via.
MX2009006446A (es) Derivados de espiro-piperidina.
CA2509090A1 (en) Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists
DE602006016244D1 (de) Diazaspiro-ä4,4ü-nonanderivate als neurokinin-(nk1)-antagonisten
JO2526B1 (en) Substituted 1-4 Dipyridine-4-YL-Piprazine derivatives and their use as NSAIDs
MXPA05003778A (es) Derivados sustituidos de la 1,4-di-piperidin-4-il-piperazina y su uso como antagonistas de neurocininas.
BR0317667A (pt) Derivados de 1-piperidin-3-il-4-piperidin-4-il-piperazina substituìdos e seu uso como antagonistas de neurocinina
MX2023005678A (es) Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activacion de plaquetas.
TH78668A (th) อนุพันธ์ 1-พิเพอริดิน-4-อิล-4-พิร์โรลิดิน-3-อิล-พิเพอแรซีนที่ถูกแทนที่และการใช้สารเหล่านั้นเป็นแอนทากอนิสท์ของนิวโรไคนิน
TH78668B (th) อนุพันธ์ 1-พิเพอริดิน-4-อิล-4-พิร์โรลิดิน-3-อิล-พิเพอแรซีนที่ถูกแทนที่และการใช้สารเหล่านั้นเป็นแอนทากอนิสท์ของนิวโรไคนิน
TH69077A (th) อนุพันธ์เฮทเทอโรไซคลิกไอโซแซซอลีนที่หลอมรวม และการใช้สารเป็นยารักษาโรคที่ซึมเศร้า

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1581517

Country of ref document: EP